Here's the latest news from Santéand its portfolio companies
Portfolio
Geneos Therapeutics Announces Scientific Meeting Presentation of Sustained Immunosurveillance and Progression-free Survival in Two Brain Cancer Patients Treated with Neoantigen Targeted Personalized DNA Immunotherapy
Portfolio
Sonire Therapeutics Completes Enrollment in SUNRISE-I Randomized Controlled Trial of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer
Portfolio
Iterion Therapeutics Reports First Clinical Validation of Tegavivint as a Targeted Therapy for Wnt-Driven Advanced HCC in Oral Presentation at 2026 ASCO Annual Meeting
Portfolio
Reimagine Care: Interview With Chief Growth Officer John Elliott About The At-Home Cancer Care Platform
Portfolio
Accrete Health Partners Invests in REVELOHEALTH® to Strengthen Contract Performance and Reimbursement Accuracy
Portfolio
Sensorium Therapeutics to Present SNTX-2643 Mechanistic Data and Phase 1a Study Design at ASCP 2026
Portfolio
Apreo Health® Adds Independent Director and Strategic Investor to Advance Novel Airway Scaffold for Severe Emphysema
Portfolio
Personalized DNA Vaccine Shows Immune Activation and Survival Signals in Glioblastoma Trial
Portfolio
Iterion Therapeutics Announces Oral Presentation of Phase 1/2 Tegavivint Data in Advanced Hepatocellular Carcinoma at the 2026 ASCO Annual Meeting
Portfolio
Sonire Therapeutics Closes $18 Million Series A Financing to Advance Breakthrough HIFU Therapy for Pancreatic Cancer, Expands U.S. Clinical Development
Santé
Biotech VCs, used to a winning formula in drug development, face disruption
Portfolio
E2 (Endovascular Engineering) Raises $80 Million Series C to Advance Next-Generation Thrombectomy Platform as Pulmonary Embolism Treatment Evolves
Santé
Measured Conviction: How Santé Ventures is Shaping the Next Generation of Healthcare Innovation
Portfolio
ABK Biomedical and MURR Forge Long-Term Partnership to Advance Breakthrough Cancer Therapy
Portfolio
Endogenex nets $50M to carry intestinal diabetes procedure to the FDA
Portfolio
Iterion Therapeutics Expands Clinical Development of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, into Colorectal Cancer with First Patient Dosed
